See more : OXE Marine AB (publ) (OXE.ST) Income Statement Analysis – Financial Results
Complete financial analysis of CONMED Corporation (CNMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CONMED Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Sysmex Corporation (SSMXF) Income Statement Analysis – Financial Results
- Mewah International Inc. (MV4.SI) Income Statement Analysis – Financial Results
- Mudanjiang Hengfeng Paper Co.,Ltd (600356.SS) Income Statement Analysis – Financial Results
- WG TECH (Jiang Xi) Co., Ltd. (603773.SS) Income Statement Analysis – Financial Results
- Auto Italia Holdings Limited (ATTGF) Income Statement Analysis – Financial Results
CONMED Corporation (CNMD)
About CONMED Corporation
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.24B | 1.05B | 1.01B | 862.46M | 955.10M | 859.63M | 796.39M | 763.52M | 719.17M | 734.47M | 756.76M | 767.14M | 725.08M | 713.72M | 694.74M | 742.18M | 694.29M | 646.81M | 617.31M | 558.39M | 497.13M | 453.06M | 428.72M | 392.23M | 372.60M | 336.40M | 138.30M | 125.60M | 99.60M | 71.10M | 53.60M | 42.60M | 38.50M | 31.40M | 19.90M | 14.20M | 12.50M | 10.50M |
| Cost of Revenue | 568.50M | 474.23M | 442.60M | 402.16M | 430.38M | 390.52M | 365.35M | 355.19M | 337.47M | 336.00M | 350.29M | 361.30M | 350.14M | 348.34M | 357.41M | 359.80M | 345.16M | 333.97M | 304.28M | 271.50M | 237.43M | 215.89M | 204.37M | 158.74M | 152.80M | 146.00M | 67.20M | 59.00M | 47.40M | 34.90M | 26.90M | 20.30M | 18.40M | 15.30M | 11.70M | 7.50M | 6.40M | 5.50M |
| Gross Profit | 676.25M | 571.25M | 568.04M | 460.30M | 524.72M | 469.11M | 431.04M | 408.33M | 381.70M | 398.47M | 406.47M | 405.84M | 374.93M | 365.38M | 337.33M | 382.38M | 349.13M | 312.85M | 313.02M | 286.89M | 259.70M | 237.17M | 224.35M | 233.49M | 219.80M | 190.40M | 71.10M | 66.60M | 52.20M | 36.20M | 26.70M | 22.30M | 20.10M | 16.10M | 8.20M | 6.70M | 6.10M | 5.00M |
| Gross Profit Ratio | 54.33% | 54.64% | 56.21% | 53.37% | 54.94% | 54.57% | 54.12% | 53.48% | 53.08% | 54.25% | 53.71% | 52.90% | 51.71% | 51.19% | 48.56% | 51.52% | 50.29% | 48.37% | 50.71% | 51.38% | 52.24% | 52.35% | 52.33% | 59.53% | 58.99% | 56.60% | 51.41% | 53.03% | 52.41% | 50.91% | 49.81% | 52.35% | 52.21% | 51.27% | 41.21% | 47.18% | 48.80% | 47.62% |
| Research & Development | 52.60M | 47.15M | 43.57M | 40.47M | 45.46M | 42.19M | 32.31M | 32.25M | 27.44M | 27.78M | 25.83M | 28.21M | 28.65M | 29.65M | 31.84M | 33.11M | 30.40M | 30.72M | 25.47M | 20.21M | 17.31M | 16.09M | 14.83M | 14.87M | 12.10M | 12.00M | 3.00M | 3.00M | 2.80M | 2.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 400.14M | 355.62M | 351.80M | 338.40M | 303.09M | 293.94M | 310.73M | 302.47M | 277.71M | 276.46M | 266.31M | 272.44M | 240.54M | 234.83M | 216.69M | 183.18M | 157.45M | 141.74M | 140.56M | 124.67M | 107.20M | 93.60M | 35.30M | 31.60M | 25.60M | 21.00M | 25.30M | 14.30M | 11.90M | 10.10M | 6.90M | 5.00M | 3.90M | 3.30M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 504.71M | 454.04M | 414.75M | 373.82M | 400.14M | 355.62M | 351.80M | 338.40M | 303.09M | 293.94M | 310.73M | 302.47M | 277.71M | 276.46M | 266.31M | 272.44M | 240.54M | 234.83M | 216.69M | 183.18M | 157.45M | 141.74M | 140.56M | 124.67M | 107.20M | 93.60M | 35.30M | 31.60M | 25.60M | 21.00M | 25.30M | 14.30M | 11.90M | 10.10M | 6.90M | 5.00M | 3.90M | 3.30M |
| Other Expenses | 0.00 | -112.01M | -1.13M | -355.00K | -5.19M | 0.00 | 0.00 | -2.94M | 0.00 | 7.32M | 8.75M | 7.20M | 0.00 | 2.18M | 10.92M | 1.58M | -4.63M | 51.90M | 7.12M | 20.34M | -2.92M | 0.00 | 0.00 | 29.49M | 25.70M | 23.60M | 7.00M | 6.40M | 0.00 | 3.90M | 3.30M | 2.20M | 2.10M | 1.60M | 1.00M | 600.00K | 400.00K | 300.00K |
| Operating Expenses | 555.64M | 501.19M | 458.32M | 414.29M | 445.60M | 397.81M | 384.11M | 370.65M | 330.53M | 345.68M | 349.96M | 340.63M | 306.36M | 308.29M | 309.06M | 307.12M | 266.31M | 317.45M | 249.27M | 223.73M | 171.84M | 157.82M | 155.39M | 169.03M | 145.00M | 129.20M | 45.30M | 41.00M | 33.40M | 27.30M | 28.60M | 16.50M | 14.00M | 11.70M | 7.90M | 5.60M | 4.30M | 3.60M |
| Cost & Expenses | 1.12B | 975.42M | 900.92M | 816.45M | 875.98M | 788.33M | 749.46M | 725.84M | 667.99M | 681.68M | 700.25M | 701.93M | 656.50M | 656.63M | 666.47M | 666.92M | 611.48M | 651.42M | 553.56M | 495.23M | 409.28M | 373.71M | 359.76M | 327.77M | 297.80M | 275.20M | 112.50M | 100.00M | 80.80M | 62.20M | 55.50M | 36.80M | 32.40M | 27.00M | 19.60M | 13.10M | 10.70M | 9.10M |
| Interest Income | 0.00 | 28.91M | 35.49M | 44.05M | 42.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 39.78M | 28.91M | 35.49M | 44.05M | 42.70M | 20.65M | 18.20M | 15.36M | 6.03M | 6.11M | 5.61M | 5.73M | 6.68M | 7.11M | 7.09M | 10.37M | 16.23M | 19.12M | 15.58M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 51.40M | 49.76M | 49.79M | 52.24M | 50.99M | 61.80M | 58.55M | 55.31M | 43.88M | 45.73M | 47.87M | 46.62M | 42.69M | 41.81M | 41.28M | 32.34M | 31.53M | 29.85M | 30.79M | 26.87M | 24.85M | 22.37M | 30.15M | 29.49M | 25.70M | 23.60M | 7.00M | 6.40M | 5.00M | 3.90M | 3.30M | 2.20M | 2.10M | 1.60M | 1.00M | 600.00K | 400.00K | 300.00K |
| EBITDA | 192.48M | 7.80M | 158.38M | 113.58M | 124.91M | 133.11M | 105.48M | 90.04M | 95.05M | 98.52M | 104.11M | 111.83M | 47.06M | 94.58M | 66.52M | 111.97M | 112.53M | 25.25M | 94.53M | 89.20M | 112.71M | 101.72M | 99.11M | 93.95M | 100.50M | 84.80M | 32.80M | 32.00M | 23.80M | 12.80M | 1.40M | 8.00M | 8.20M | 6.00M | 1.30M | 1.70M | 2.20M | 1.70M |
| EBITDA Ratio | 15.46% | -4.01% | 10.74% | 5.29% | 7.74% | 8.29% | 5.89% | 11.79% | 13.22% | 13.41% | 13.79% | 14.58% | 15.34% | 13.86% | 10.01% | 14.50% | 16.07% | 12.03% | 16.47% | 19.91% | 25.30% | 22.45% | 23.12% | 23.95% | 26.97% | 25.21% | 50.04% | 25.48% | 23.90% | 18.00% | 2.99% | 18.08% | 20.52% | 19.11% | 6.03% | 10.56% | 16.80% | 16.19% |
| Operating Income | 130.79M | 70.05M | 37.85M | -26.97M | 1.60M | 71.31M | 46.94M | 37.68M | 51.18M | 52.79M | 56.51M | 65.21M | 8.27M | 57.09M | 28.27M | 75.26M | 80.99M | -4.60M | 63.75M | 63.16M | 79.96M | 79.35M | 68.96M | 64.46M | 74.80M | 61.20M | 25.80M | 25.60M | 18.80M | 8.90M | -1.90M | 5.80M | 6.10M | 4.40M | 300.00K | 1.10M | 1.80M | 1.40M |
| Operating Income Ratio | 10.51% | 6.70% | 3.74% | -3.13% | 0.17% | 8.29% | 5.89% | 4.93% | 7.12% | 7.19% | 7.47% | 8.50% | 1.14% | 8.00% | 4.07% | 10.14% | 11.67% | -0.71% | 10.33% | 11.31% | 16.08% | 17.51% | 16.08% | 16.44% | 20.08% | 18.19% | 18.66% | 20.38% | 18.88% | 12.52% | -3.54% | 13.62% | 15.84% | 14.01% | 1.51% | 7.75% | 14.40% | 13.33% |
| Total Other Income/Expenses | -49.96M | -140.92M | -36.61M | -44.41M | -47.89M | -20.65M | -18.20M | -18.30M | -6.03M | -6.11M | -5.88M | -5.73M | -59.40M | -11.44M | -10.11M | -6.00M | -13.43M | -19.80M | -15.58M | -13.60M | -26.95M | -25.99M | -30.82M | -34.29M | -32.30M | -30.90M | -36.50M | -100.00K | -2.00M | -600.00K | -200.00K | 300.00K | -200.00K | -700.00K | -100.00K | 100.00K | 0.00 | -200.00K |
| Income Before Tax | 80.83M | -70.86M | 73.11M | 1.60M | 31.23M | 50.65M | 28.73M | 19.38M | 45.14M | 46.68M | 50.63M | 59.48M | -2.31M | 45.66M | 18.16M | 69.26M | 64.76M | -24.40M | 48.17M | 49.56M | 53.01M | 54.84M | 38.13M | 30.18M | 42.50M | 30.30M | -10.70M | 25.50M | 16.80M | 8.30M | -2.10M | 6.10M | 5.90M | 3.70M | 200.00K | 1.20M | 1.80M | 1.20M |
| Income Before Tax Ratio | 6.49% | -6.78% | 7.23% | 0.19% | 3.27% | 5.89% | 3.61% | 2.54% | 6.28% | 6.35% | 6.69% | 7.75% | -0.32% | 6.40% | 2.61% | 9.33% | 9.33% | -3.77% | 7.80% | 8.88% | 10.66% | 12.10% | 8.89% | 7.69% | 11.41% | 9.01% | -7.74% | 20.30% | 16.87% | 11.67% | -3.92% | 14.32% | 15.32% | 11.78% | 1.01% | 8.45% | 14.40% | 11.43% |
| Income Tax Expense | 16.37M | 9.72M | 10.56M | -7.91M | 2.61M | 9.80M | -26.76M | 4.71M | 14.65M | 14.48M | 14.69M | 19.00M | -3.06M | 15.31M | 6.02M | 24.70M | 23.30M | -11.89M | 16.18M | 16.10M | 20.93M | 19.74M | 13.73M | 10.86M | 15.30M | 10.90M | -3.60M | 9.20M | 5.90M | 2.90M | -700.00K | 2.00M | 2.00M | 1.30M | 100.00K | 400.00K | 700.00K | 500.00K |
| Net Income | 64.46M | -80.58M | 62.54M | 9.52M | 28.62M | 40.85M | 55.49M | 14.66M | 30.50M | 32.19M | 35.94M | 40.48M | 752.00K | 30.35M | 12.14M | 44.56M | 41.46M | -12.51M | 31.99M | 33.47M | 32.08M | 34.15M | 24.41M | 19.31M | 27.20M | 17.80M | -7.10M | 16.30M | 10.90M | 5.40M | -1.40M | 4.10M | 3.90M | 2.40M | -300.00K | 800.00K | 1.10M | 700.00K |
| Net Income Ratio | 5.18% | -7.71% | 6.19% | 1.10% | 3.00% | 4.75% | 6.97% | 1.92% | 4.24% | 4.38% | 4.75% | 5.28% | 0.10% | 4.25% | 1.75% | 6.00% | 5.97% | -1.93% | 5.18% | 5.99% | 6.45% | 7.54% | 5.69% | 4.92% | 7.30% | 5.29% | -5.13% | 12.98% | 10.94% | 7.59% | -2.61% | 9.62% | 10.13% | 7.64% | -1.51% | 5.63% | 8.80% | 6.67% |
| EPS | 2.10 | -2.68 | 2.14 | 0.33 | 1.01 | 1.45 | 1.99 | 0.53 | 1.10 | 1.17 | 1.30 | 1.43 | 0.03 | 1.06 | 0.42 | 1.55 | 1.46 | -0.45 | 1.09 | 1.13 | 1.11 | 1.25 | 1.02 | 0.84 | 1.19 | 0.79 | -0.31 | 0.77 | 0.64 | 0.40 | -0.11 | 0.28 | 0.31 | 0.25 | -0.03 | 0.08 | 0.14 | 0.10 |
| EPS Diluted | 2.04 | -2.68 | 1.94 | 0.32 | 0.97 | 1.41 | 1.97 | 0.52 | 1.09 | 1.16 | 1.28 | 1.41 | 0.03 | 1.05 | 0.42 | 1.52 | 1.43 | -0.45 | 1.08 | 1.11 | 1.10 | 1.23 | 1.00 | 0.83 | 1.17 | 0.77 | -0.31 | 0.75 | 0.63 | 0.37 | -0.11 | 0.28 | 0.31 | 0.25 | -0.03 | 0.08 | 0.14 | 0.10 |
| Weighted Avg Shares Out | 30.67M | 30.04M | 29.16M | 28.58M | 28.33M | 28.12M | 27.94M | 27.80M | 27.65M | 27.40M | 27.72M | 28.30M | 28.25M | 28.72M | 29.07M | 28.80M | 28.39M | 27.79M | 29.35M | 29.62M | 28.90M | 27.32M | 23.93M | 22.99M | 22.91M | 22.63M | 22.65M | 21.07M | 17.04M | 13.49M | 13.12M | 14.64M | 12.71M | 9.72M | 11.24M | 10.00M | 7.85M | 7.00M |
| Weighted Avg Shares Out (Dil) | 31.55M | 30.04M | 32.22M | 29.46M | 29.50M | 28.89M | 28.17M | 27.96M | 27.86M | 27.77M | 28.11M | 28.65M | 28.63M | 28.91M | 29.14M | 29.23M | 28.99M | 27.79M | 29.62M | 30.15M | 29.17M | 27.77M | 24.41M | 23.27M | 23.17M | 23.02M | 22.65M | 21.82M | 17.42M | 14.46M | 13.12M | 14.64M | 12.71M | 9.72M | 11.24M | 10.00M | 7.85M | 7.00M |
Conmed (CNMD) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Conmed (CNMD) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Conmed (CNMD) Surpasses Q1 Earnings and Revenue Estimates
Conmed (CNMD) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.66 per share a year ago.
CONMED Corporation Promotes Patrick Beyer to Chief Operating Officer
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Patrick Beyer, President of International and Global Orthopedics, has been promoted to the newly created role of Chief Operating Officer (COO), effective immediately. In this role, Mr. Beyer will take on...
CONMED Corporation Announces First Quarter 2024 Financial Results
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights Sales of $312.3 million increased 5.7% year-over-year as reported and 5.9% in constant currency. Domestic revenue increased 7.2%...
Here's Why You Should Retain CONMED (CNMD) Stock for Now
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
CONMED Corporation to Announce First Quarter 2024 Financial Results on April 24, 2024
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the first quarter 2024 after the market close on Wednesday, April 24, 2024. The Company's management will host a conference call at 4:30 p.m. ET...
3 Retirement Stocks to Buy at a 52-Week Low in March
Despite significant challenges, the U.S. economy has showcased remarkable resilience. Fears of an imminent recession have been allayed by two consecutive quarters of robust GDP growth exceeding 3%.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
CONMED (CNMD) Misses on Q4 Earnings, Beats Revenue Estimates
CONMED's (CNMD) adjusted fourth-quarter earnings misses while sales beat estimates on the back of strong growth in the United States and international markets. Gross margin improves with a rise in sales.
CONMED Corporation (CNMD) Q4 2023 Earnings Call Transcript
CONMED Corporation (CNMD) Q4 2023 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports